Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption

AIDS Research and Human Retroviruses

Volumn 24, Issue 12, 2008, Pages 1485-1495

  Mestre, Gabriel ^a   Garcia, Felipe ^a,b,d   Martinez, Esteban ^a   Milinkovic, Ana ^a   Lopez, Anna ^a,b   León, Agathe ^a,b   Mora, Borja ^a,b   Argelich, Roger ^a,b   Lozano, José Manuel ^c   Peña, José ^c   Gatell, José M ^a,b   Plana, Montserrat ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; CD3 ANTIGEN; CD56 ANTIGEN; FC RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CELL POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADULT; BIOSYNTHESIS; CD4 LYMPHOCYTE COUNT; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE SUBPOPULATION; MALE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIROLOGY; VIRUS LOAD;

ADULT; ANTIGENS, CD3; ANTIGENS, CD56; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; RECEPTORS, IGG; RECEPTORS, KIR; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 58149123466     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0135     Document Type: Article

References (29)

1. Autran B and Carcelain G: AIDS. Boosting immunity to HIV - can the virus help? Science 2000;290:946-949.
2. Nuesch R and Hirschel B: Treatment interruption for convenience, cost cutting and toxicity sparing. Curr Opin HIV AIDS 2007;2(31):38.
3. SMART Study Group: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
4. Tarwater PM, Parish M, and Gallant JE: Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003;37(11):1541-1548.
5. Maggiolo F, Ripamonti D, Gregis G, et al.: Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial. AIDS 2004;18(3):439-446.
6. Wit FW, Blanckenberg DH, Brinkman K, et al.: Safety of long-term interruption of successful antiretroviral therapy: The ATHENA cohort study. AIDS 2005;19(3):345-348.
7. Nuesch R, Ananworanich J, Sirivichayakul S, et al.: Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005;40(5):728-734.
8. Giuntini R, Martinelli C, Ambu S et al.: Prolonged treatment interruption in chronic HIV infection: A new strategy? AIDS 2005;19(2):209-211.
9. Fagard C, Bandelier CY, Ananworanich J, et al.: Biphasic decline of CD4 cell count during scheduled treatment interruptions. AIDS 2005;19(4):439-441.
10. Oxenius A, Price D, Gunthard HF, et al.: Stimulation of HIV specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV-infection. Proc Natl Acad Sci USA 2002;99:13747-13752.
11. Fagard C, Oxenius A, Gunthard H, et al.: A prospective trial of structured treatment interruptions in HIV infection. Arch Intern Med 2003;163:1220-1226.
12. García F, Plana M, Ortiz GM, et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-F40.
13. Carcelain G, Tubiana R, Samri A, et al.: Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001;75:234-241.
14. Ruiz L, Carcelain G, Martinez-Picado J, et al.: HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F19-F27.
15. Ortiz GM, Wellons M, Brancato J, et al.: Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 2001;98:13288-13293.
16. 3. J Acquir Immune Defic Syndr 2004;36:791-799.
17. Libois A, Lopez A, Garcia F, et al.: Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of ART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses 2006;22(7):657-666.
18. Alter G, Teigen N, Ahern R, et al.: Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007;195(10):1452-1460.
19. Mela CM, Burton CT, Imami N, et al.: Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: Lack of reversion with highly active antiretroviral therapy. AIDS 2005;19(16):1761-1769.
20. De MA, Fogli M, Costa P, et al.: The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003;33(9):2410-2418.
21. Fauci AS, Mavilio D, and Kottilil S: NK cells in HIV infection: Paradigm for protection or targets for ambush. Nat Rev Immunol 2005;5(11):835-843.
22. Papasavvas E, Kostman JR, Mounzer K, et al.: Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PloS Med 2004;1(3):e64.
23. Jacobson JM, Pat BR, Spritzler J, et al.: Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: The results of AIDS Clinical Trials Group 5068. J Infect Dis 2006;194(5):623-632.
24. Scott-Algara D and Paul P: NK cells and HIV infection: Lessons from other viruses. Curr Mol Med 2002;2(8):757-768.
25. Mavilio D, Lombardo G, Benjamin J, et al.: Characterization of CD56-/CD16+ natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005;102(8):2886-2891.
26. Tarazona R, Casado JG, Delarosa O, et al.: Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 2002;22(3):176-183.
27. Tarazona R, Delarosa O, Casado JG, et al.: NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: Defective expression of CD56. AIDS 2002;16(2):197-200.
28. Vallejo A, Valladares A, De FB, et al.: High thymic volume is associated with viral replication and immunologic impairment only early after ART interruption in chronic HIV infection. Viral Immunol 2005;18(4):740-746.
29. Molina-Pinelo S, Vivancos J, De FB, et al.: Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption. J Acquir Immune Defic Syndr 2006;42(2):203-206.